Megan Edwards, MD
Infectious Disease · Springfield, MANPI 1730446535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Insmed, Inc. accounts for 61.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $246 and has fallen 62.5% since, to $92 in 2025.
Across 63 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$556
- Gilead$121
- Cumberland Pharmaceuticals, Inc.$54
- Medline Industries LP$29
- AstraZeneca$27
- AbbVie$25
- plus $86 from 5 others
What the payments were for
- Food & beverage$87698%
- Education$222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 51 | $556 |
| Gilead | 2 | $121 |
| Cumberland Pharmaceuticals, Inc. | 2 | $54 |
| Medline Industries LP | 1 | $29 |
| AstraZeneca | 1 | $27 |
| AbbVie | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Eisai Inc. | 1 | $15 |
How this compares
$898 in reported general payments places this provider in the 70th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Springfield
- Claudia MartorellSpringfield$990K
- Yoav GolanBoston$1.1M
- Nesli BasgozBoston$901K
- Todd EllerinBoston$843K
- Peter SebenyNewburyport$343K
- Paul SaxBoston$320K
- Davidson HamerBoston$221K
- Camille KottonBoston$195K
- David SnydmanBoston$141K
- Eric RosenbergBoston$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.